What is Kane Biotech Inc?
, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally.
KNBIF · Verdict
Moderate reward · elevated risk
KNBIF stands out on volatility and growth, but watch the balance sheet signal.
Based on 88% data coverage
KNBIF · Verdict
Top decile vs peers
Revenue +9.0% CAGR
Current ratio 0.43
293% net margin · -597% ROE
-202% free-cash-flow margin
Below average
Model-based scoring. For information only — not financial advice.
, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG) for treating wounds and otic infections. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 4.59M.
The scoring profile indicates limited reward potential at this time, with growth and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.